跳至主要内容
临床试验/EUCTR2008-006763-36-BG
EUCTR2008-006763-36-BG进行中(未招募)不适用

Randomized, double-blind study comparing the immunogenicity of two different brands of human insulin for the treatment of diabetes

Marvel Life Sciences Limited0 个研究点目标入组 500 人开始时间: 2009年3月27日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • [[1]male and female patients suffering from type 1 or type 2 diabetes mellitus for at least 6 months before randomization
  • [2]negative screening assay for antibodies against insulin before the start of treatment
  • [3]age 18-75 years
  • [4]Body Mass Index (BMI) =35 kg/m2
  • [5]informed consent given in a written form after being provided with detailed information about the nature, risks, and scope of the clinical trial as well as the expected desirable and adverse effects of the drug
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • [1]Previous exposure to Humulin®
  • [2]known hypersensitivity against insulin or any of the inactive components of the formulations
  • [3]known extreme resistance to insulin (daily dose of more than 200 IU)
  • [4severe renal failure (NKF stage 4-5) or patients on hemodialysis
  • [5]severe cardiac failure (NYHA III-IV)
  • [6]myocardial infarction within the last 6 months before randomization
  • [7]unstable angina pectoris
  • [8]stroke within the last 6 months before randomization
  • [9]liver failure with ascites
  • [10]severe peripheral vascular disease with ulceration or amputation
  • [11]cancer
  • [12concomitant treatment with corticosteroids (except stable dose of inhaled corticosteroids)
  • [13]concomitant treatment with immunosuppressive agents (e.g. cyclosporine A, methotrexate, etc.)
  • [14]concomitant treatment with somatotropine
  • [15]pregnancy or lactation period in female patients
  • [16]severe physical or mental concomitant diseases that might hamper the realization of the trial according to protocol or the evaluation of efficacy or safety
  • [17]anamnestic or current alcohol abuse i.e. consumption of more than 10 units of alcohol per week or a history of alcoholism or drug/chemical abuse (one unit of alcohol equals 250 ml of beer, 125 ml wine or 25 ml of spirits)
  • [18]participation in another clinical trial within the last 12 weeks
  • [19]legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequences of the study
  • [20]unreliability or lack of cooperation
  • [21]lack of a possibility to attend the visits required by protocol.

研究者

发起方
Marvel Life Sciences Limited

相似试验

已完成
3 期
A clinical trial Comparing the immunogenicity of two different brands of human Insulin for the treatment of diabetes.
CTRI/2009/091/000862Spectrum Clinical Research Pvt Ltd500
进行中(未招募)
不适用
Randomized, double-blind study comparing the immunogenicity of two different brands of human insulin for the treatment of diabetesPatients suffering from diabetes mellitus type 1 or 2 with the indication for insulin treatment and dependent on insulin administration.MedDRA version: 9.1Level: PTClassification code 10012608Term: Diabetes mellitus insulin-dependentMedDRA version: 9.1Level: PTClassification code 10018209Term: Gestational diabetesMedDRA version: 9.1Level: PTClassification code 10049746Term: Insulin-requiring type II diabetes mellitusMedDRA version: 9.1Level: PTClassification code 10051599Term: Diabetes mellitus managementMedDRA version: 9.1Level: PTClassification code 10012601Term: Diabetes mellitus
EUCTR2008-006763-36-DEMarvel Life Sciences Limited500
进行中(未招募)
不适用
Randomized, double-blind, study to compare the incidence and intensity lf neurologic and pschiatic adverse events of efavirenz when given as a stepped dosage (200 mg qd for 6 days, 400 mg qd for 7 days and 600 mg qd from the day 14 farward) with the usual dosage (600 mg qd from first day)Pacientes infectados por el VIH a los que su medico responsable les haya prescrito efavirez como parte de su tratamiento antiretroviralMedDRA version: 6.0Classification code 10008919
EUCTR2005-003243-31-ESuis Fernando López Cortés100
进行中(未招募)
不适用
A randomized, double-blind study comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs metformin alone in patients with type 2 diabetes mellitus and dyslipidemia not appropriately controlled with a statin. - fenofibrate and metformin fixed combination vs metformi
EUCTR2006-000924-15-CZFOURNIER Laboratories Ireland Ltd480
进行中(未招募)
不适用
A randomized, double-blind study comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs metformin alone in patients with type 2 diabetes mellitus and dyslipidemia not appropriately controlled with a statin - fenofibrate and metformin fixed combination vs metformiPatients with type 2 diabetes mellitus and dyslipidemia not appropriately controlled with a statin
EUCTR2006-000924-15-HUFOURNIER Laboratories Ireland Ltd480